Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
- Resource Type
- Authors
- Shashikant Srivastava; Gunavanthi D. Boorgula; Jann-Yuan Wang; Hung-Ling Huang; Dave Howe; Tawanda Gumbo; Scott K. Heysell
- Source
- Antimicrobial Agents and Chemotherapy. 66
- Subject
- Lung Diseases
Pharmacology
Infectious Diseases
Mycobacterium kansasii
Antitubercular Agents
Humans
Mycobacterium Infections, Nontuberculous
Pharmacology (medical)
Microbial Sensitivity Tests
Rifampin
Retrospective Studies
- Language
- ISSN
- 1098-6596
0066-4804
There is limited high-quality evidence to guide the optimal treatment of Mycobacterium kansasii pulmonary disease. We retrospectively collected clinical data from 33 patients with M. kansasii pulmonary disease to determine the time-to-sputum culture conversion (SCC) upon treatment with a standard combination regimen consist of isoniazid-rifampin-ethambutol. Next, MIC experiments with 20 clinical isolates were performed, followed by a dose-response study with the standard laboratory strain using the hollow-fiber system model of M. kansasii infection (HFS- Mkn ). The inhibitory sigmoid maximum effect ( E max ) model was used to describe the relationship between the bacterial burden and rifampin concentrations.